BioXcel Therapeutics Inc.: The Losing Streak Continues (BTAI)

July 7, 2021 11:02:05

BioXcel Therapeutics Inc. (NASDAQ:BTAI) traded today at a new 52-week low of $26.67. So far today approximately 204,000 shares have been exchanged, as compared to an average 30-day volume of 448,000 shares.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.

In the past 52 weeks, shares of BioXcel Therapeutics Inc. have traded between the current low of $26.67 and a high of $71.50 and is now at $27.23.

Potential upside of 3.8% exists for BioXcel Therapeutics Inc., based on a current level of $27.23 and analysts’ average consensus price target of $28.27.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer